Recent progress of study on mechanism of immune thrombocytopenic purpura and its clinical treatment - review

Immune thrombocytopenia purpura (ITP) is a disorder mediated by antiplatelet antibodies and characterized by accelerated destruction of platelets and impaired platelet production. The mainstay therapies for ITP have included corticosteroids, the immune globulin intravenous immunoglobulin and IV anti...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 16; no. 5; p. 1232
Main Authors Lu, Xue-Chun, Zhu, Hong-Li, Yao, Shan-Qian
Format Journal Article
LanguageChinese
Published China 01.10.2008
Subjects
Humans
Purpura, Thrombocytopenic, Idiopathic - classification
Purpura, Thrombocytopenic, Idiopathic - immunology
Purpura, Thrombocytopenic, Idiopathic - therapy
Online AccessGet more information

Cover

More Information
Summary:Immune thrombocytopenia purpura (ITP) is a disorder mediated by antiplatelet antibodies and characterized by accelerated destruction of platelets and impaired platelet production. The mainstay therapies for ITP have included corticosteroids, the immune globulin intravenous immunoglobulin and IV anti-D (monoclonal antibodies against the D antigen of the Rh system), vinblastine or a monoclonal anti-CD20 antibody that transiently depletes CD20(+) B cells, danazol, cyclophosphamide and even splenectomy to refractory one. Most of ITP patients responded to those treatment, while more than 30% of whom may relapse sooner or later. The recombinant forms of human TPO were discontinued from human use in clinic because recipients of these agents developed significant thrombocytopenia secondary to production of neutralizing antibodies that cross-reacted with endogenous TPO. All above mentioned treatments have side effects and severe infection may arise post splenectomy. The more powerful treatment with less side effects a
ISSN:1009-2137